(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
-4.26% € 682.60
Live Chart Being Loaded With Signals
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...
Stats | |
---|---|
Dzisiejszy wolumen | 7 966.00 |
Średni wolumen | 6 577.00 |
Kapitalizacja rynkowa | 648.75B |
EPS | €0 ( 2024-04-30 ) |
Last Dividend | €1.130 ( 2023-08-14 ) |
Next Dividend | €0 ( N/A ) |
P/E | 107.50 |
ATR14 | €0.943 (0.14%) |
Wolumen Korelacja
Eli Lilly and Co Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Eli Lilly and Co Korelacja - Waluta/Towar
Eli Lilly and Co Finanse
Annual | 2023 |
Przychody: | €34.12B |
Zysk brutto: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2023 |
Przychody: | €34.12B |
Zysk brutto: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2022 |
Przychody: | €28.54B |
Zysk brutto: | €21.91B (76.77 %) |
EPS: | €6.93 |
FY | 2021 |
Przychody: | €28.32B |
Zysk brutto: | €21.01B (74.18 %) |
EPS: | €5.83 |
Financial Reports:
No articles found.
Eli Lilly and Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.980 (N/A) |
€0.980 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.490 | 2009-05-13 |
Last Dividend | €1.130 | 2023-08-14 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 41 | -- |
Total Paid Out | €27.35 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.94 | -- |
Div. Sustainability Score | 7.36 | |
Div.Growth Potential Score | 6.18 | |
Div. Directional Score | 6.77 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VH2.DE | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
DYH.DE | Ex Dividend Knight | 2023-11-14 | Quarterly | 0 | 0.00% | |
NTG.DE | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% | |
AAD.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
GBF.DE | Ex Dividend Knight | 2023-06-02 | Annually | 0 | 0.00% | |
PWO.DE | Ex Dividend Junior | 2023-05-11 | Sporadic | 0 | 0.00% | |
AWC.DE | Ex Dividend Junior | 2023-08-07 | Quarterly | 0 | 0.00% | |
IBM.DE | Ex Dividend Knight | 2023-08-09 | Quarterly | 0 | 0.00% | |
SWTF.F | Ex Dividend Junior | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
CIS.DE | Ex Dividend Knight | 2023-10-03 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.171 | 1.500 | 6.58 | 9.88 | [0 - 0.5] |
returnOnAssetsTTM | 0.0960 | 1.200 | 6.80 | 8.16 | [0 - 0.3] |
returnOnEquityTTM | 0.535 | 1.500 | 5.16 | 7.74 | [0.1 - 1] |
payoutRatioTTM | 0.688 | -1.000 | 3.12 | -3.12 | [0 - 1] |
currentRatioTTM | 1.354 | 0.800 | 8.23 | 6.58 | [1 - 3] |
quickRatioTTM | 0.677 | 0.800 | -0.721 | -0.577 | [0.8 - 2.5] |
cashRatioTTM | 0.132 | 1.500 | -0.376 | -0.564 | [0.2 - 2] |
debtRatioTTM | 0.410 | -1.500 | 3.17 | -4.75 | [0 - 0.6] |
interestCoverageTTM | 15.16 | 1.000 | 5.50 | 5.50 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.06 | 2.00 | 8.65 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -4.31 | 2.00 | -2.15 | -4.31 | [0 - 20] |
debtEquityRatioTTM | 2.05 | -1.500 | 1.817 | -2.73 | [0 - 2.5] |
grossProfitMarginTTM | 0.802 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.237 | 1.000 | 7.25 | 7.25 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.140 | 1.000 | -0.332 | -0.332 | [0.2 - 2] |
assetTurnoverTTM | 0.562 | 0.800 | 9.59 | 7.67 | [0.5 - 2] |
Total Score | 7.36 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 108.28 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.535 | 2.50 | 6.89 | 7.74 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -4.31 | 2.00 | -1.436 | -4.31 | [0 - 30] |
dividendYielPercentageTTM | 0.638 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.06 | 2.00 | 8.65 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.688 | 1.500 | 3.12 | -3.12 | [0 - 1] |
pegRatioTTM | 9.48 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.102 | 1.000 | 9.94 | 0 | [0.1 - 0.5] |
Total Score | 6.18 |
Eli Lilly and Co
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej